Related Experiment Video
Updated: Aug 2, 2026
08:16
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Comparative genomic hybridization analysis of hepatoblastomas
1Department of Pathology, the Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
Genes, Chromosomes & Cancer
|December 29, 1999
Summary
This study investigated genetic changes in hepatoblastoma, finding common gains in chromosomes 1, 2, 17, and 20. Researchers identified specific amplified regions, suggesting potential targets for future hepatoblastoma research.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Hepatoblastoma, a rare pediatric liver cancer, exhibits complex cytogenetic abnormalities.
- Previous studies identified trisomy for chromosomes 2 and 20 and translocations involving chromosomes 1 and 4.
- Gene amplification, suggested by double minute chromosomes, was observed but specific amplified genes remained unidentified.
Purpose of the Study:
- To investigate cytogenetic alterations in hepatoblastoma pathogenesis and progression.
- To identify recurrent genomic gains and losses using comparative genomic hybridization.
- To explore potential gene amplification sites in hepatoblastoma.
Main Methods:
- Comparative genomic hybridization (CGH) was performed on 10 hepatoblastoma tumors.
- Analysis focused on identifying regions of genomic gain and loss.
- Specific loci with high-level gains were examined for amplification.
Main Results:
- Nine out of ten tumors showed regions of genomic gain or loss.
- Recurrent abnormalities included gain of chromosome 1 long arm (6 tumors), chromosome 2 (7 tumors), chromosome 17 (4 tumors), and chromosome 20 (3 tumors).
- Losses were observed on chromosomes 4 and 11 (2 tumors each).
- High-level gains were detected at 1q32 and 2q24 in four cases, suggesting potential amplification sites.
Conclusions:
- Comparative genomic hybridization reveals frequent chromosomal aberrations in hepatoblastoma.
- Specific amplified regions at 1q32 and 2q24 warrant further investigation for candidate oncogenes.
- Identifying amplified genes could provide novel therapeutic targets for hepatoblastoma treatment.
